[VIRTUAL] Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up

[VIRTUAL] Pevonedistat + azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia: a phase 2 randomized study

[VIRTUAL] Addition of parsaclisib (INCB050465), a PI3Kd inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis

[VIRTUAL] CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel in relapsed/ Refractory multiple myeloma

[VIRTUAL] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/ Refractory multiple myeloma: first results from the CC-220-MM-001 study

[VIRTUAL] Primary analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-hodgkin lymphoma

[VIRTUAL] Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel as first-line therapy in patients with high-risk large B-cell lymphoma

[VIRTUAL] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton’s Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

[VIRTUAL] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30- positive peripheral T-cell lymphoma: 5-year results

[VIRTUAL] One year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/Refractory mantle cell lymphoma

[VIRTUAL] Pharmacological profile and clinical outcomes of KTE-X19 by prior bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/ refractory mantle cell lymphoma in the ZUMA-2 trial

[VIRTUAL] Efficacy and safety of mogamulizumab by patient blood classification

[VIRTUAL] Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single- agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma

[VIRTUAL] CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/ intolerant to jak inhibitor: update from phase 2 manifest study

[VIRTUAL] A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis